Esophageal carcinoma: Towards targeted therapies
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, squamous carcinoma is the most common pathogenic form of esophageal cancer in China [18].Its growth rate and pathological changes are diferent from those of adenocarcinoma [19], so the patient may experience diverse symptoms and thus interpret them variously.”
From Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study. (2023) · cites this paper as [19]
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Research works printed but not linked: 1
- Available from: https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/keynote-181-in-esophageal-cancer/. Accessed 19 October 2019
Cited by
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer
Yao, Z., Yang, Y., Sun, M., He, Y., Liao, L., Chen, K., & Li, B. (2022) · Cancer Communications · doi:10.1002/cac2.12254 · Cited by 288
Advances and challenges in the treatment of esophageal cancer
He, S., Xu, J., Liu, X., & Zhen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.008 · Cited by 287
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1
Guo, H., Wang, B., Xu, K., Nie, L., Fu, Y. S., Wang, Z., Wang, Q., Wang, S., & Zou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.553045 · Cited by 140
Zhu, P., Yu, H., Zhou, K., Bai, Y., Qi, R., & Zhang, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01618-7 · Cited by 57
Metadata
- Authors
- Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J.
- Affiliations
- Western University (CA)
- Venue
- Cellular Oncology
- Published
- 2019-12-17
- Volume
- 43
- Issue
- 2
- Pages
- 195-209
- ISSN
- 1570-5870 (ISSN-L)
- 2211-3428
- 2211-3436
- PMC
- PMC12990719
- OpenAlex
- W2994654968
- Cited by
- 158
- References
- 83
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 29 · 2023: 20 · 2022: 44 · 2021: 29 · 2020: 14
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cellular Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- esophageal squamous cell carcinoma, esophageal adenocarcinoma, targeted therapy, pembrolizumab, PD-L1, ramucirumab, trastuzumab, CDK4/6 inhibitors, PARP inhibitors, Nrf2 signaling, Wnt signaling, genomic profiling, biomarkers, metastatic esophageal cancer
- MeSH terms
- Adenocarcinoma, Carcinoma, Squamous Cell, Enzyme Inhibitors, Esophageal Neoplasms, Humans, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.